Levofloxacin Mesylate for Injection

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about twice that of ofloxacin. Its main mechanism of action is to inhibit the activity of bacterial DNA gyrase (bacterial topoisomerase II) and hinder the replication of bacterial DNA to achieve antibacterial effect. This product has the characteristics of broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Escherichia coli, Klebsiella, Serratia, Proteus, Shigella, Salmonella, Citrobacter, Acinetobacter, and Gram-negative bacteria such as Pseudomonas aeruginosa, Haemophilus influenzae, and Neisseria gonorrhoeae. It also has good antibacterial effect on some methicillin-sensitive Staphylococci, Streptococcus pneumoniae, Streptococcus pyogenes, hemolytic Streptococci, and Legionella, Mycoplasma, and Chlamydia, but has poor effect on anaerobic bacteria and enterococci.

Levofloxacin mesylate.

This product is off-white or light yellow loose mass or powder.

This product is suitable for the following moderate and severe infections caused by sensitive bacteria: respiratory system infections: acute bronchitis, acute exacerbation of chronic bronchitis, diffuse bacterial bronchitis, bronchiectasis and infection, pneumonia, tonsillitis (peritonsillar abscess); urinary system infections: pyelonephritis, complicated urinary tract infection, etc.; reproductive system infections: acute prostatitis, acute epididymitis, uterine cavity infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic infection is suspected); skin and soft tissue infections: infectious impetigo, cellulitis, lymphangiitis (adenitis), subcutaneous abscess, perianal abscess, etc.; intestinal infections: bacillary dysentery, infectious enteritis, salmonella enteritis, typhoid and paratyphoid; various infections in patients with sepsis, neutropenia and immunodeficiency; other infections: mastitis, trauma, burns and postoperative wound infection, abdominal infection (metronidazole can be used in combination when necessary), cholecystitis, cholangitis, bone and joint infection and ENT infection, etc.

Before use, dissolve it in 100ml of 0.9% sodium chloride injection or 5% glucose injection and drip it intravenously. Adults take 0.4g per day, divided into 2 intravenous drips. For patients with severe infections and those with poor sensitivity of pathogens to this product (such as Pseudomonas aeruginosa), the maximum daily dose can be increased to 0.6g, divided into 2 intravenous drips. For patients with impaired renal function, the dosage is determined according to the creatinine clearance rate: creatinine clearance rate 50-80ml/min normal dose 20-49ml/min first dose 0.4g 0.2g every 24 hours thereafter, 10-19ml/min first dose 0.4g 0.2g every 48 hours thereafter, this preparation is specially for intravenous drip, and the drip time is at least 60 minutes per 100ml. This preparation should not be mixed with other drugs in the same bottle for intravenous drip, or dripped in the same intravenous infusion tube. Or follow the doctor's advice.

During medication, symptoms such as nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, and bloating may occur; neurological symptoms such as insomnia, dizziness, and headache; rash, itching, erythema, and redness and itching at the injection site or phlebitis may occur. Transient liver function abnormalities may also occur, such as increased blood transaminase and increased serum total bilirubin. The incidence of the above adverse reactions is between 0.1 and 5%. Occasionally, blood urea nitrogen rises, fatigue, fever, palpitations, abnormal taste, etc., which are generally tolerated and disappear quickly after the end of the course of treatment.

It is contraindicated for patients who are allergic to quinolones, pregnant or lactating women, and patients under 18 years of age.

1. This product cannot be used in the same infusion tube with multivalent metal ion solutions such as magnesium and calcium. Avoid using it simultaneously with theophylline. If simultaneous use is necessary, the blood concentration of theophylline should be monitored and the dosage adjusted accordingly. 2. When used simultaneously with warfarin or its derivatives, the prothrombin time or other coagulation tests should be monitored. 3. When used simultaneously with non-steroidal anti-inflammatory drugs, convulsions may be induced. 4. When used simultaneously with oral hypoglycemic drugs, hypoglycemia may be caused. Therefore, attention should be paid to monitoring the blood concentration during medication. Once hypoglycemia occurs, this product should be discontinued immediately and appropriate treatment should be given.

Keep away from light and store in sealed container.

0.3g (calculated as levofloxacin)

Wuhan Hiteck Biological Pharma Co., Ltd.

• Founded in:

  1992-04-08

• Address:

  Wuhan Economic and Technological Development Zone Haite Technology Park

• Tax NO.:

  91420100724667038L

• Registered Funds:

  130.894391 yuan

• Website:

  Log in to view

• Email:

  Log in to view